Lumida
/SVRA
⌘K
Savara Inc

Savara Inc

SVRA
$5.52USD+0.00%+0.00 today

MARKET CAP

1.1B

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $6

52W RANGE

$2
$7

AI Summary

Stalk
StalkMedium

SVRA remains in a Stage 2 advancing uptrend marked by a clear higher-high/higher-low sequence, underpinning a bullish medium-term bias. After peaking in early July, price has pulled back into the rising 50-day MA and the 200-day MA confluence, with short EMAs sloping lower and short-term momentum deteriorating. Without a Lockout Rally override, execution timing is unfavorable now and should be deferred, stalking for a pullback acceptance at key support. Overall, maintain medium-term bullish stance while waiting for supportive price action around the 50-DMA zone.

  • FDA accepted MOLBREEVI BLA with PDUFA set for Nov 22 2026.
  • IMPALA-2 trial enrollment completes mid-2026; topline data in H1 2027.
  • No Q1 2026 revenue; net loss of $0.15/share vs -$0.1374 est.
Full analysis →
Insider Trades21 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jun 22, 2026SellSVRADavid L LowranceChief Financial Officer1,160,374$3.69$1.1B-21.20%+144.25%$4.3M+0.00%Buy Now
Mar 18, 2026BuySVRADavid L LowranceChief Financial Officer483,507$2.43$1.1B-21.20%+144.25%$1.2M+4.12%Buy Now
Dec 14, 2025SellSVRAKathleen R. MccabeChief Legal Officer39,350$6.92$1.1B-21.20%+144.25%$272.3K-7.04%Buy Now
Dec 14, 2025SellSVRAAnne EricksonChief Business Officer62,960$6.92$1.1B-21.20%+144.25%$435.7K-14.48%Buy Now
Dec 14, 2025SellSVRADavid L LowranceChief Financial Officer94,960$4.59$1.1B-21.20%+144.25%$435.7K-13.58%Buy Now
Dec 14, 2025SellSVRARobert Matthew LutzChief Operating Officer67,760$6.92$1.1B-21.20%+144.25%$468.9K-18.73%Buy Now
Dec 14, 2025SellSVRAMatthew PaulsCHIEF EXECUTIVE OFFICER324,700$4.17$1.1B-21.20%+144.25%$1.4M-11.47%Buy Now
Dec 10, 2025SellSVRAMatthew PaulsCHIEF EXECUTIVE OFFICER23,629$6.69$1.1B-21.20%+144.25%$158.1K-1.54%Buy Now
Dec 4, 2025SellSVRAYasmine WasfiChief Medical Officer21,992$6.37$1.1B-21.20%+144.25%$140.1K-11.57%Buy Now
Feb 13, 2025SellSVRARobert Matthew LutzChief Operating Officer38,263$2.83$1.1B-21.20%+144.25%$108.3K-9.57%Buy Now
Dec 13, 2024SellSVRAAnne EricksonChief Business Officer18,263$3.21$1.1B-21.20%+144.25%$58.6K-2.43%Buy Now
Dec 13, 2024SellSVRADavid L LowranceChief Financial Officer61,350$2.63$1.1B-21.20%+144.25%$161.4K-3.89%Buy Now
Dec 13, 2024SellSVRAMatthew PaulsCHIEF EXECUTIVE OFFICER147,295$3.25$1.1B-21.20%+144.25%$478.1K-3.53%Buy Now
Nov 10, 2024SellSVRARaymond Dennis PrattChief Medical Officer49,950$3.97$1.1B-21.20%+144.25%$198.3K-16.11%Buy Now
Oct 21, 2024SellSVRAAnne EricksonChief Business Officer381$3.57$1.1B-21.20%+144.25%$1.4K-0.11%Buy Now
Jul 21, 2024SellSVRAAnne EricksonChief Business Officer381$4.47$1.1B-21.20%+144.25%$1.7K-0.11%Buy Now
Apr 21, 2024SellSVRAAnne EricksonChief Business Officer381$4.81$1.1B-21.20%+144.25%$1.8K-0.11%Buy Now
Dec 28, 2023SellSVRADavid L LowranceCHIEF FINANCIAL OFFICER10,000$4.71$1.1B-21.20%+144.25%$47.1K-2.84%Buy Now
Dec 28, 2023SellSVRAMatthew PaulsCHIEF EXECUTIVE OFFICER103,000$3.84$1.1B-21.20%+144.25%$395.9K-3.83%Buy Now
Dec 14, 2023SellSVRADavid L LowranceCHIEF FINANCIAL OFFICER50,438$2.69$1.1B-21.20%+144.25%$135.4K-7.70%Buy Now
Dec 14, 2023SellSVRAMatthew PaulsCHIEF EXECUTIVE OFFICER109,680$4.45$1.1B-21.20%+144.25%$488.1K-8.63%Buy Now